Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyPresbyterian Fecal Analysis Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentPresbyterian Health PlanPolicy AHS-G2060

    Fecal Analysis in the Diagnosis of Intestinal Dysbiosis and Fecal Microbiota Transplant Testing

    Customize your policy alerts

    Sign up for Presbyterian Health Plan Policy AHS-G2060 alerts

    Get alerted when Policy AHS-G2060 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of selected fecal analyses used before fecal microbiota transplant donation and fecal analyses proposed for diagnosing intestinal dysbiosis, irritable bowel syndrome, malabsorption, or small intestinal bacterial overgrowth. Coverage criteria apply to members according to their applicable benefit plan.

    Policy Summary
    PayerPresbyterian Health Plan
    PolicyFecal Analysis in the Diagnosis of Intestinal Dysbiosis and Fecal Microbiota Transplant Testing
    Policy CodePolicy AHS-G2060
    Change TypeBackground, guideline, reference, and clarity updatesno material coverage change
    Effective DateFeb 1, 2026
    Next Review DateN/A
    Key ActionComplete FMT donor health questionnaires and laboratory screening before and after the stool-donation period.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    The policy was reviewed and updated with revisions to the background, guidelines and recommendations, and evidence-based scientific references.

    Prior revisions clarified that the fecal microbiota transplant test is performed on the donor-derived sample and clarified criterion CC4h.

    7Covered donor bacterial culture targets
    8Covered donor NAAT targets
    4Noncovered donor NAAT targets
    14Noncovered dysbiosis-related analysis components
    4Minimum MDRO screening categories
    60 daysMaximum interval between bookend MDRO tests

    Coverage Criteria

    Covered donor bacterial culture

    Covered when performed before FMT donation on the donor fecal sample by bacterial culture for at least one of the following microorganisms:

    Testing context and target

    • Testing context: Testing is performed before donation for a fecal microbiota transplant on the donor fecal sample.
    • Covered bacterial culture target

      • Microorganism: Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae.
      • Microorganism: Vancomycin-resistant Enterococci (VRE).
      • Microorganism: Carbapenem-resistant Enterobacteriaceae (CRE).
      • Microorganism: Methicillin-resistant Staphylococcus aureus (MRSA).
      • Microorganism: Campylobacter.
      • Microorganism: Shigella.
      • Microorganism: Salmonella.

    Covered donor NAAT

    Covered when performed before FMT donation on the donor fecal sample by NAAT for at least one of the following microorganisms:

    Testing context and target

    • Testing context: Testing is performed before donation for a fecal microbiota transplant on the donor fecal sample.
    • Covered NAAT target

      • Microorganism: Clostridium difficile.
      • Microorganism: Campylobacter.
      • Microorganism: Salmonella.

    Noncovered donor NAAT

    The following donor fecal NAAT performed before FMT donation does not meet coverage criteria:

    Noncovered NAAT target

    • Microorganism: Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae.
    • Microorganism: Vancomycin-resistant Enterococci (VRE).
    • Microorganism: Carbapenem-resistant Enterobacteriaceae (CRE).
    • Microorganism: Methicillin-resistant Staphylococcus aureus (MRSA).

    Noncovered dysbiosis-related fecal analysis

    Fecal analysis used diagnostically to evaluate intestinal dysbiosis, irritable bowel syndrome, malabsorption, or small intestinal bacterial overgrowth does not meet coverage criteria when it includes any of the following:

    Noncovered fecal analysis component

    • Triglycerides.
    • Chymotrypsin.
    • Iso-butyrate, iso-valerate, and n-valerate.
    • Meat and vegetable fibers.
    • Long-chain fatty acids.
    • Cholesterol.

    Diagnostic stool testing

    Guideline-supported stool testing may be appropriate in the following clinical circumstances when infectious or inflammatory causes are being evaluated:

    Clinical circumstance

    • Diarrhea, including evaluation for bacterial, viral, or parasitic causes and consideration of Clostridium difficile testing.
    • Symptoms of active Crohn's disease, with testing for fecal pathogens and Clostridium difficile; fecal calprotectin may also be used to assess gut inflammation.
    • Suspected ulcerative colitis, including stool cultures and Clostridium difficile toxin testing to rule out infectious causes.
    • An acute colitis flare, including stool cultures for enteroinvasive bacterial infections and Clostridium difficile testing.
    • Inflammatory bowel disease or suspected inflammatory bowel disease, including stool microbiological analysis and Clostridium difficile testing.

    FMT for recurrent or refractory C. difficile infection

    FMT may be considered primarily for recurrent or refractory C. difficile infection in the following circumstances:

    Clinical circumstance

    • Severe or fulminant C. difficile infection refractory to antibiotic therapy when the patient is a poor surgical candidate.
    • Second or subsequent recurrence of C. difficile infection, including use to prevent further recurrences through capsule or colonoscopy; enema may be used when other methods are unavailable.
    • Recurrence of C. difficile infection within 8 weeks of an initial FMT, for which repeat FMT may be considered.within 8 weeks
    • Recurrent C. difficile infection in a patient with inflammatory bowel disease.

    Donor fecal NAAT performed before FMT donation does not meet coverage criteria for ESBL-producing Enterobacteriaceae, VRE, CRE, MRSA, or any other microorganism not specifically listed as covered. Some of these organisms may meet criteria when tested by bacterial culture, but not by donor-sample NAAT.

    Fecal analysis does not meet coverage criteria when used diagnostically to evaluate intestinal dysbiosis, irritable bowel syndrome, malabsorption, or small intestinal bacterial overgrowth and measures triglycerides, chymotrypsin, selected short- or long-chain fatty acids, meat or vegetable fibers, cholesterol, microbial or yeast quantities, beta-glucuronidase, pH, short-chain fatty-acid distribution, or fecal secretory IgA.

    Conventional FMT is not recommended, or evidence is insufficient, for functional gastrointestinal symptoms, IBS, ulcerative colitis, Crohn's disease, or pouchitis outside clinical trials. The principal supported use discussed in the evidence is recurrent or refractory C. difficile infection; inflammatory bowel disease complicated by C. difficile infection is treated differently from FMT used for the underlying bowel disorder alone.

    Donors or stool testing positive for multidrug-resistant organisms (MDROs) should not be used for FMT. At a minimum, screening should include ESBL-producing Enterobacteriaceae, VRE, CRE, and MRSA. FDA guidance permits bookend testing no more than 60 days apart before and after multiple donations when stool is quarantined until post-donation results are confirmed negative.

    Tests do not meet coverage criteria when published scientific literature does not confirm that they are required and beneficial for diagnosing and treating the individual's illness.

    Applicable Procedure Codes

    Applicable CPT/HCPCS Procedure Codesmixed
    82542Column chromatography, includes mass spectrometry, if performed (e.g., HPLC, LC, LC/MS, LC/MS-MS, GC, GC/MS-MS, GC/MS, HPLC/MS), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen.
    82705Fat or lipids, feces; qualitative.
    82710Fat or lipids, feces; quantitative.
    82715Fat differential, feces, quantitative.
    83986pH; body fluid, not otherwise specified.
    84311Spectrophotometry, analyte not elsewhere specified.
    87076Culture, bacterial; anaerobic isolate, additional methods required for definitive identification, each isolate.
    87077Culture, bacterial; aerobic isolate, additional methods required for definitive identification, each isolate.
    87081Culture, presumptive, pathogenic organisms, screening only.
    87102Culture, fungi (mold or yeast) isolation, with presumptive identification of isolates; other source (except blood).
    1–10 of 17
    1/2

    Provider Documentation and Action Items

    Documentation Required

    Document Donor Questionnaire and Screening

    Before and after the period of stool donation, document completion of the donor health questionnaire and required laboratory screening assays. Maintain screening documentation for the donor and the stool-screening results in the FMT record.

    • Document a completed donor health questionnaire.
    • Document laboratory screening before and after the donation period.
    • Include stool screening for C. difficile; Campylobacter, Salmonella, and Shigella; Shiga toxin-producing E. coli; multidrug-resistant bacteria; ova, cysts, and parasites; Cryptosporidium and Giardia; Cyclospora and Isospora; H. pylori; norovirus; and rotavirus.
    • Document applicable serum screening separately from stool screening.
    Documentation Required

    Document COVID-19 Donor Screening

    Document the FDA-required COVID-19 donor screening assessment and testing for each donor and donation. Do not use donation material when required screening information or testing is absent.

    Clinical Background

    Intestinal dysbiosis is a disruption or imbalance of intestinal microbial ecology and has been associated with gastrointestinal and systemic conditions. Although microbiome profiling and FMT have been studied in multiple settings, the evidence outside recurrent or refractory C. difficile infection remains limited or heterogeneous, and standardized diagnostic methods and normal biomarker ranges are lacking.

    Key Definitions and Abbreviations

    Intestinal dysbiosis
    TermIntestinal dysbiosis
    DefinitionA disruption or imbalance of the intestinal microbial ecology.
    Associated conditionsAssociated with conditions including irritable bowel syndrome, inflammatory bowel diseases, celiac disease, multiple sclerosis, Sjogren's syndrome, obesity, allergy, and diabetes.
    FMT
    AbbreviationFMT
    Expanded termFecal microbiota transplant
    DefinitionA transplant involving fecal microbiota.

    Covered Clinical Indications

    Donor fecal sample analysis before donation for FMT

    Donor fecal sample analysis before donation for FMT meets coverage criteria when the testing uses the specified method and target:

    Testing method and target

    • Covered testing method

      • Bacterial culture of the donor fecal sample before FMT donation for any of the following: ESBL-producing Enterobacteriaceae, VRE, CRE, MRSA, Campylobacter, Shigella, or Salmonella.
      • NAAT of the donor fecal sample before FMT donation for any of the following: Clostridium difficile, Campylobacter, Salmonella, Shigella, Shiga toxin-producing Escherichia coli, Norovirus, Rotavirus, or COVID-19 (SARS-CoV-2).

    Evaluation of diarrhea, inflammatory bowel disease, and prolonged gastrointestinal symptoms

    Guideline-supported stool testing may be considered when evaluating infectious or inflammatory causes in patients with:

    Testing Frequency and Timing

    FMT donor MDRO screening
    Testing intervalBookend MDRO testing before and after multiple stool donations may be performed no more than 60 days apart.
    Stool quarantineStool samples must be quarantined until post-donation MDRO test results are confirmed negative.
    Minimum screening targetsScreening must include ESBL-producing Enterobacteriaceae, vancomycin-resistant enterococci, carbapenem-resistant Enterobacteriaceae, and methicillin-resistant Staphylococcus aureus.

    Ordering and Documentation Requirements

    Documentation Required

    Meet FMT donor screening requirements

    For FMT donor screening, obtain a donor health questionnaire and laboratory screening before and after the stool-donation period. Evaluate the donor for SARS-CoV-2 infection, COVID-19 symptoms, or exposure, and arrange SARS-CoV-2 testing of the donor or stool donation when applicable.

    • Document the completed donor health questionnaire.
    • Document pre- and post-donation laboratory screening.
    • Record SARS-CoV-2 history, symptoms, exposure assessment, and applicable testing.

    Services That Do Not Meet Coverage Criteria

    Not covered: donor fecal NAAT performed before FMT donation for ESBL-producing Enterobacteriaceae, VRE, CRE, MRSA, or any other microorganism not listed among the covered NAAT targets.

    Not covered: fecal analysis used to evaluate intestinal dysbiosis, IBS, malabsorption, or small intestinal bacterial overgrowth when it measures triglycerides, chymotrypsin, iso-butyrate, iso-valerate, n-valerate, meat or vegetable fibers, long-chain fatty acids, cholesterol, total short-chain fatty acids, microbial or potential-pathogen quantities, fecal yeast, N-butyrate, beta-glucuronidase, pH, short-chain fatty-acid distribution, or fecal secretory IgA.

    Not covered: conventional FMT for functional gastrointestinal symptoms, IBS, ulcerative colitis, Crohn's disease, or pouchitis when used outside a clinical trial and without a complicating C. difficile infection. Guidelines describe this use as not recommended, investigational, or supported by limited or very low-quality evidence.

    Other FMT indications described in the evidence as unsupported or insufficiently evidenced include treatment of inflammatory bowel disease itself, ulcerative colitis, Crohn's disease, pouchitis, and functional gastrointestinal symptoms. FMT remains investigational for IBD outside clinical trials unless the condition is complicated by C. difficile infection.

    Policy Summary
    PayerPresbyterian Health Plan
    PolicyFecal Analysis in the Diagnosis of Intestinal Dysbiosis and Fecal Microbiota Transplant Testing
    Policy CodePolicy AHS-G2060
    Change TypeBackground, guideline, reference, and clarity updatesno material coverage change
    Effective DateFeb 1, 2026
    Next Review DateN/A
    Key ActionComplete FMT donor health questionnaires and laboratory screening before and after the stool-donation period.
    SourceLink
    On This Page
    Coverage CriteriaApplicable Procedure CodesProvider Documentation and Action ItemsClinical BackgroundKey Definitions and AbbreviationsCovered Clinical IndicationsTesting Frequency and TimingOrdering and Documentation RequirementsServices That Do Not Meet Coverage Criteria
  1. Microorganism: Shigella.
  2. Microorganism: Shiga toxin-producing Escherichia coli.
  3. Microorganism: Norovirus.
  4. Microorganism: Rotavirus.
  5. Microorganism: COVID-19 (SARS-CoV-2).
  6. Microorganism:
    Any other microorganism not listed as covered.
  7. Total short-chain fatty acids.
  8. Quantification of Lactobacilli, bifidobacteria, E. coli, and other potential pathogens, including Aeromonas, Bacillus cereus, Campylobacter, Citrobacter, Klebsiella, Proteus, Pseudomonas, Salmonella, Shigella, S. aureus, and Vibrio.
  9. Identification and quantitation of fecal yeast, including C. albicans, C. tropicalis, Rhodotorula, and Geotrichum.
  10. N-butyrate.
  11. Beta-glucuronidase.
  12. pH.
  13. Short-chain fatty acid distribution.
  14. Fecal secretory IgA.
  15. Severe illness, chronic underlying conditions, or prolonged gastrointestinal symptoms when specific treatment is being considered.
  16. A patient who has recovered from severe, fulminant, or particularly treatment-refractory C. difficile infection, or has significant comorbidities or a high risk of recurrent or morbid recurrence.
    • Assess whether, since December 1, 2019, the donor had laboratory-confirmed SARS-CoV-2 infection.
    • Assess COVID-19 symptoms, including fever, cough, or shortness of breath, when not explained by another diagnosis.
    • Assess exposure to a suspected or confirmed COVID-19 case or SARS-CoV-2 infection.
    • Document SARS-CoV-2 virus or RNA testing of the stool donation or donor; acceptable approaches may include nasal, rectal, or stool specimens.
    Denial Risk

    Noncovered Donor NAAT Targets

    NAAT testing of donor stool for the targets below does not meet coverage criteria. Do not represent these tests as covered FMT donor screening under this policy.

    • Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae
    • Vancomycin-resistant Enterococci (VRE)
    • Carbapenem-resistant Enterobacteriaceae (CRE)
    • Methicillin-resistant Staphylococcus aureus (MRSA)
    • Any other microorganism not specifically listed as meeting coverage criteria
    Denial Risk

    Noncovered Dysbiosis-Related Fecal Analysis

    Fecal analysis of the following components does not meet coverage criteria when used to evaluate intestinal dysbiosis, irritable bowel syndrome, malabsorption, or small intestinal bacterial overgrowth. Do not use these analyses as covered diagnostic testing under this policy.

    • Triglycerides; chymotrypsin; iso-butyrate, iso-valerate, and n-valerate; meat and vegetable fibers; long-chain fatty acids; cholesterol; and total short-chain fatty acids
    • Quantification of Lactobacilli, bifidobacteria, E. coli, and other potential pathogens, including Aeromonas, Bacillus cereus, Campylobacter, Citrobacter, Klebsiella, Proteus, Pseudomonas, Salmonella, Shigella, S. aureus, and Vibrio
    • Identification and quantitation of fecal yeast, including C. albicans, C. tropicalis, Rhodotorula, and Geotrichum; N-butyrate; beta-glucuronidase; pH; short-chain fatty-acid distribution; and fecal secretory IgA
    Denial Risk

    Insufficient Clinical Evidence

    Tests and analyses lack coverage when available published scientific literature does not confirm that they are required and beneficial for diagnosing and treating the individual's illness. Document the clinical indication and medical-necessity rationale, and do not assume coverage for tests without published evidence supporting clinical necessity and benefit.

    • Apply this limitation to testing used for intestinal dysbiosis, irritable bowel syndrome, malabsorption, or small intestinal bacterial overgrowth when the policy does not identify the test as meeting coverage criteria.
    • Review the policy's covered and noncovered test lists before ordering or billing.
    Denial Risk

    Do Not Use MDRO-Positive Donors or Stool

    Do not use donors or stool that test positive for multidrug-resistant organisms (MDROs) for FMT. Quarantine stool when bookend testing is used and release it only after required post-donation MDRO tests are confirmed negative.

    • At minimum, screen for ESBL-producing Enterobacteriaceae, VRE, CRE, and MRSA.
    • Nasal or perirectal culture is an acceptable alternative to stool testing for MRSA only.
    • Bookend testing may occur no more than 60 days apart before and after multiple donations, provided stool samples remain quarantined until post-donation MDRO results are confirmed negative.
    • Exclude any donor or stool with a positive MDRO result.
    CDI
    AbbreviationCDI
    Expanded termClostridium difficile infection
    DefinitionInfection caused by Clostridium difficile.
    NAAT
    AbbreviationNAAT
    Expanded termNucleic acid amplification testing
    DefinitionTesting that amplifies nucleic acid to detect a target organism or genetic material.
    ESBL
    AbbreviationESBL
    Expanded termExtended spectrum beta-lactamase
    DefinitionAn extended spectrum beta-lactamase.
    CRE
    AbbreviationCRE
    Expanded termCarbapenem-resistant Enterobacteriaceae/Enterobacterales
    DefinitionEnterobacteriaceae or Enterobacterales that are resistant to carbapenems.
    VRE
    AbbreviationVRE
    Expanded termVancomycin-resistant enterococci
    DefinitionEnterococci that are resistant to vancomycin.
    SIBO
    AbbreviationSIBO
    Expanded termSmall intestinal bacterial overgrowth
    DefinitionBacterial overgrowth in the small intestine.
    SBBO
    AbbreviationSBBO
    Expanded termSmall bowel bacterial overgrowth
    DefinitionBacterial overgrowth in the small bowel.
    SCFA
    AbbreviationSCFA
    Expanded termShort-chain fatty acids
    DefinitionShort-chain fatty acids.
    Laboratory-developed test (LDT)
    TermLaboratory-developed test (LDT)
    DefinitionA test developed, validated, and performed in-house by a laboratory.
    Regulatory contextCMS regulates LDTs as high-complexity tests under the Clinical Laboratory Improvement Amendment of 1988 (CLIA '88); FDA clearance or approval is not currently required for clinical use.
    Fecal microbiota-based therapies
    Therapy type 1Conventional fecal microbiota transplantation
    Therapy type 2Fecal microbiota live-jslm
    Therapy type 3Fecal microbiota spores live-brpk

    Clinical circumstance

    • Diarrhea.
    • Suspected or active inflammatory bowel disease.
    • An acute colitis flare.
    • Suspected ulcerative colitis, including evaluation with stool cultures and Clostridium difficile toxin testing.
    • Suspected Crohn's disease or active Crohn's disease, including evaluation with fecal pathogen and Clostridium difficile testing; fecal calprotectin may be included to identify gut inflammation.
    • Severe illness or an underlying chronic condition.
    • Prolonged gastrointestinal symptoms when specific treatment is being considered.

    Screening of fecal donors for FMT

    FMT donor screening should include a health questionnaire and laboratory screening before and after the stool-donation period. Screening should address the following:

    Donor screening requirements

    • Timing: Complete donor health assessment and laboratory screening both before and after the period of stool donation.
    • Required screening category

      • Infectious and enteric pathogens

        • Clostridium difficile testing, including toxin B PCR when available.
        • Routine bacterial culture and/or PCR for Campylobacter, Salmonella, Shigella, and other enteric pathogens.
        • Shiga toxin-producing Escherichia coli by PCR.
      • Parasitic testing

        • Stool ova, cysts, and parasite analysis, including Microsporidia.
        • Fecal Giardia and Cryptosporidium antigen testing.
        • Acid-fast stain for Cyclospora and Isospora.
      • Viral and other infectious testing

        • Norovirus and rotavirus PCR.
        • Helicobacter pylori fecal antigen.
      • Multidrug-resistant organism screening

        • Minimum MDRO targets: Screen at minimum for ESBL-producing Enterobacteriaceae, VRE, CRE, and MRSA.
        • Use of positive donors or stool: Donors or stool testing positive for MDROs should not be used for FMT.
        • Bookend testing: Before- and after-donation MDRO testing may be no more than 60 days apart for multiple stool donations, with stool quarantined until post-donation MDRO results are confirmed negative.no more than 60 days apart